BioCentury
ARTICLE | Clinical News

Keytruda monotherapy non-inferior to chemotherapy in first-line gastric cancer

May 3, 2019 9:34 PM UTC

Merck said April 25 that Keytruda pembrolizumab as monotherapy met the primary endpoint of non-inferiority to standard-of-care chemotherapy in improving overall survival (OS) in the Phase III KEYNOTE-062 trial as first-line treatment of gastric cancer. The pharma said the trial could serve as a potential confirmatory trial for the PD-1 inhibitor's accelerated approval.

In September 2017, FDA granted accelerated approval to Keytruda as third-line treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1...